What is HC Wainwright’s Forecast for Genmab A/S Q2 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities research analysts at HC Wainwright lowered their Q2 2027 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Friday, November 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.44 for the quarter, down from their prior forecast of $0.59. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.22 per share.

Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. upgraded shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a report on Monday, October 26th. Morgan Stanley raised their price objective on shares of Genmab A/S from $42.00 to $57.00 and gave the company an “equal weight” rating in a report on Friday, October 30th. Truist Financial reaffirmed a “buy” rating and set a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. TD Cowen boosted their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, October 26th. Finally, New Street Research set a $43.00 target price on Genmab A/S in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $53.61.

Genmab A/S Stock Up 4.0%

Shares of NASDAQ:GMAB opened at $55.80 on Monday. The firm’s 50 day moving average price is $39.63 and its 200 day moving average price is $31.22. The stock has a market cap of $34.82 billion, a price-to-earnings ratio of 39.65, a price-to-earnings-growth ratio of 2.17 and a beta of 0.73. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $59.97. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.20 billion.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bessemer Group Inc. raised its holdings in Genmab A/S by 38.6% during the third quarter. Bessemer Group Inc. now owns 729 shares of the company’s stock worth $26,000 after purchasing an additional 203 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Genmab A/S during the 2nd quarter worth approximately $31,000. Nykredit A S purchased a new stake in shares of Genmab A/S during the 2nd quarter worth approximately $58,000. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 16.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock valued at $109,000 after buying an additional 561 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Genmab A/S by 51.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,597 shares of the company’s stock valued at $123,000 after buying an additional 1,565 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.